Table of Content

1. Introduction To DLL3 Targeted Therapies
1.1 Overview
1.2 History & Evolution Of DLL3 Targeted Therapies
1.3 Role Of DLL3 As Diagnostic & Prognostic Markers


2. DLL3 Targeting Approaches, Mechanism & Commercial Aspects
2.1 Antibody Drug Conjugates
2.2 Antibodies
2.3 Cell Therapies
2.4 Antibody Radionuclide Conjugates
2.5 Antibody Photoabsorber/Photosensitizer Conjugate


3. DLL3 Targeted Therapies Proprietary Platforms
3.1 Platforms Used To Develop DLL3 Targeted Therapies
3.2 Potential Platforms For DLL3 Targeted Therapies Development


4. Imdelltra – 1st Approved DLL3 Targeted Drug
4.1 Clinical Overview & Patent Insight
4.2 Treatment Cycle Pricing & Dosage Analysis
4.3 Sales Analysis


5. DLL3 Targeted Therapies Market & Clinical Trends Insights
5.1 Current Market Trends, Developments & Clinical Trials Assessment
5.2 Future Commercialization Opportunity


6. DLL3 Targeted Therapies Research & Market Trends by Region
6.1 US
6.2 UK
6.3 EU
6.4 Canada
6.5 Australia
6.6 China


7. Global DLL3 Targeted Therapies Clinical Development & Market Insight By Indication
7.1 Small Cell Lung Cancer
7.2 Large Cell Neuroendocrine Cancer
7.3 Neuroendocrine Prostate Cancer
7.4 Gastroenteropancreatic Neuroendocrine Tumors
7.5 Glioma


8. Global DLL3 Targeted Drugs Clinical Trials Overview
8.1 By Company
8.2 By Fast Track Status
8.3 By Indication
8.4 By Location
8.5 By Patient Segment
8.6 By Phase


9. Global DLL3 Targeted Drugs Clinical Trials By Company, Indication & Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II


10. Marketed DLL3 Targeted Drugs Clinical Trials By Company, Indication & Phase


11. DLL3 Targeted Therapies Market Dynamics
11.1 Favorable Market & Clinical Development Parameters
11.2 Challenges & Restraints


12. Key Companies Involved In Research & Development Of DLL3 Targeted Therapies
12.1 Abdera Therapeutics
12.2 Allogene Therapeutics
12.3 Amgen
12.4 Boehringer Ingelheim
12.5 Chugai Pharmaceutical
12.6 Gensun Biopharma
12.7 Harpoon Therapeutics
12.8 ImaginAb Inc
12.9 Legend Biotech
12.10 Molecular Partners
12.11 Phanes Therapeutics
12.12 Qilu Pharmaceutical
12.13 Shanghai Affinity Biopharmaceutical
12.14 ZAI Lab
 



List of Figures

Figure 2-1: Antibody Drug Conjugates - Mechanism Of Action
Figure 2-2: BiTE – Amgen
Figure 2-3: HPN328 - Structure
Figure 2-4: Rova-IR700 - Mechanism

Figure 3-1: T-Charge Platform - Features
Figure 3-2: BiTE? Antibody Construct
Figure 3-3: TMALIN – ADC Advantages
Figure 3-4: TMALIN – ADC Structure
Figure 3-5: TriTAC - T-Cell Engagers Structure
Figure 3-6: TriTAC - Advantages
Figure 3-7: PACbody? Platform
Figure 3-8: ATACCbody? Platform
Figure 3-9: SPECpair? Platform
Figure 3-10: ROVEr Platform - Process
Figure 3-11: RPT - Advantages
Figure 3-12: Dual-Ig Technology – Antibody Structure & Mechanism
Figure 3-13: AlloCAR T - Process
Figure 3-14: AlloCAR T - Features
Figure 3-15: Alluminox? Platform - Drug Structure
Figure 3-16: Rakuten Medical - Photoimmunotherapy Process

Figure 4-1: Imdelltra – Approval Year By Region
Figure 4-2: US – Price of Supply of Imdelltra Intravenous Powder (US$), January’2025
Figure 4-3: EU – Price Of Imdelltra Intravenous Powder (US$), January’2025:
Figure 4-4: Global – Imdelltra Sales (US$ Million), 2024
Figure 4-5: Imdelltra – Global Sales By Quarter (US$ Million), Q2 & Q3’2024
Figure 4-6: Imdelltra - US Sales (US$ Million), 2024
Figure 4-7: Imdelltra– US Sales By Quarter (US$ Million), Q2 & Q3’2024

Figure 5-1: Global – DLL3 Targeted Therapy Market (US$ Million), 2024
Figure 5-2: Global – DLL3 Targeted Therapy Market Sales (US$ Million), Q2 & Q3’2024

Figure 7-1: DLL3 - Small Cell Lung Cancer
Figure 7-2: DeLLphi-301 Phase 2 Study – Initiation & Completion Year
Figure 7-3: DeLLphi-304 Phase 2 Study – Initiation & Completion Year
Figure 7-4: DAREON?-5 Phase 2 Study – Initiation & Completion Year
Figure 7-5: PT217X1101 Phase 1 Study – Initiation & Completion Year
Figure 7-6: HPN328 Phase 1 Study – Initiation & Completion Year
Figure 7-7: LB2102-1001 Phase 1 Study – Initiation & Completion Year
Figure 7-8: NCT05507593 Phase 1 Study – Initiation & Completion Year
Figure 7-9: DLL3 – Large Cell Neuroendocrine Cancer

Figure 8-1: Global - DLL3 Targeted Drugs Clinical Trials By Company (Number), 2025
Figure 8-2: Global - DLL3 Targeted Drugs Clinical Trials By Fast Track Status (Number), 2025
Figure 8-3: Global - DLL3 Targeted Drugs Clinical Trials By Indication (Number), 2025
Figure 8-4: Global - DLL3 Targeted Drugs Clinical Trials By Location (Number), 2025
Figure 8-5: Global - DLL3 Targeted Drugs Clinical Trials By Patient Segment (Number), 2025
Figure 8-6: Global - DLL3 Targeted Drugs Clinical Trials By Phase (Number), 2025

Figure 11-1: DLL3 Targeted Therapies – Market Drivers & Opportunities
Figure 11-2: DLL3 Targeted Therapies – Market Challenges & Restraints

List of Tables

Table 6-1: US – FDA Designated DLL3 Targeted Therapies, 2025
Table 7-1: Large Cell Neuroendocrine Cancer – Candidates In Clinical Trials, 2025
Table 7-2: Neuroendocrine Prostate Cancer – Candidates In Clinical Trials, 2025
Table 7 3: Gastroenteropancreatic Neuroendocrine Tumors – Candidates In Clinical Trials, 2025
Table 7-4: Glioma – Candidates In Clinical Trials, 2025